Healthcare Industry News:  asenapine 


 News Release - November 28, 2006

Organon and Pfizer Discontinue Their Collaboration on Asenapine

NEW YORK and ARNHEM, Netherlands, Nov. 28 (HSMN NewsFeed) -- Organon and Pfizer today announced that they have agreed to discontinue their collaboration in the further development of asenapine, a new drug candidate for the treatment of schizophrenia and acute mania associated with Bipolar I Disorder.

Pfizer's decision to discontinue its participation in the asenapine development program is an outcome of a commercial analysis of the compound as a part of its overall portfolio. Pfizer will return all product rights, intellectual property and data to Organon and make orderly transitions during 2007.

Organon will continue to develop asenapine.

Source: Pfizer

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.